ClinicalTrials.gg
RecruitingNCT07119424Updated Aug 13, 2025

Multidisciplinary Dissection of Renal and Metabolic Effects of Glyfozines on Elderly Patients: From Molecular Aspects to Clinical Indications

An observational study in Elderly Patients (>65 Years), Diabetes (DM) and Heart Disease, sponsored by Chiara Lanzani. Recruiting at 1 site in Italy. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-08-13.

Sponsored by Chiara Lanzani · Observational

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
300
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 270 studies in Diabetes Mellitus with a site in Italy — 31 open to participants now, 42 under way, 3 of them phase 3. Diabetes Mellitus · Italy.

Planned enrollment
36th of 67
300 · median 406
Started
2025
with 11 others
Observational
67 of 270
15 open now
Primary completion
2026-11
later than 22 of 41 live
Registered
258th of 270
by date

Among the 270 studies in Diabetes Mellitus with a site in Italy, this one is the 36th largest by planned enrollment of the 67 observational ones that give a count, is one of 12 that started in 2025, is one of 67 observational ones, reaches primary completion later than 22 of the 41 other live ones, and was the 258th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

31 of the 270 studies in Diabetes Mellitus with a site in Italy are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 65 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 270 studies in Diabetes Mellitus with a site in Italy, or all of them as a file.
02

Study summary

The project aims to study the impact of SGLT2i therapy on clinical and biochemical aspects. in elderly. The project will combine different types of data, such as clinical and biological information, and will use advanced Bayesian statistical methods to understand the relationship between risk factors and patient outcomes following treatment with SGLT2 inhibitors.

03

Conditions studied

  • Elderly Patients (>65 Years)
  • Diabetes (DM)
  • Heart Disease
  • Renal Diseases
  • Internal Disease
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients aged ≥65 years, either females or males, who have just been prescribed, in accordance with clinical practice and due to clinical reasons independent of the study, a SGLT2i for any clinical indication for SGLT2i use, who have not yet started SGLT2i therapy, and yet not under SGLT2i treatment. Patients must be enrolled also in MED-Cli e MED-Mol studies by signing both the MED-Cli e MED-Mol informed consents.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant is willing and able to give for participation in the study;
  2. Patients must be enrolled also in MED-Cli e MED-Mol studies by signing both the MED-Cli e MED-Mol informed consents.
  3. The medical product is the standard of care for the patient and has been prescribed according to clinical practice and independent of the present study;
  4. Age ≥65 years;
  5. Participant has not yet started the prescribed SGLT2i therapy;
  6. Participant has at least one clinical indication for SGLT2i use according to clinical practice guidelines.

Exclusion criteria

Exclusion Criteria:

  1. Current or previous use of SGLT2i;
  2. Inability to sign the .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
300 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes

Groups and cohorts

  • Subjects with Nephrological, Diabetologic, Cardiological and Internal diseases

    Patients aged ≥65 years, either females or males, who have just been prescribed, in accordance with clinical practice and due to clinical reasons independent of the study, a SGLT2i for any clinical indication for SGLT2i use, who have not yet started SGLT2i therapy, and yet not under SGLT2i treatment.

06

What researchers measure

Primary outcomes

  1. Patient health status prior and after 6 months of SGLT2i therapy through Frailty Index variation (FI)

    Patient health status prior and after 6 months of SGLT2i therapy through Frailty Index variation (FI). The FI is score measured by comparing the ratio of health deficits present within an individual to possible health deficits, using a pre-specified list of 30 or more deficits. Deficits included in the model will be collected during the visit trough questionnaires and clinical and biochemical evaluation

    Time frame: From enrollment to 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Nov 2026, 21 months after the start.

Of 534 non-industry observational studies under Diabetes Mellitus, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 159. This study's planned 21 months is below that.

Counting every sponsor, half of 643 studies reached it within 36 months; a quarter within 14 and three quarters within 122.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2025
First posted
Aug 13, 2025
StartActual
Feb 14, 2025
Primary completionEst.
Nov 2026
CompletionEst.
Feb 2027
Last update
Aug 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07119424
Lead sponsor
Chiara Lanzani
Responsible party
Chiara Lanzani (Professor, Ospedale San Raffaele) — Sponsor-investigator
First posted
Aug 13, 2025
Start date
Feb 14, 2025
Primary completion
Nov 2026 (estimated)
Completion
Feb 2027 (estimated)
Last update
Aug 13, 2025

Study contacts

Chiara Livia Lanzani, professor
Contact
lanzani.chiara@hsr.it
00390226438131
Federica Guerra, Dr
Contact
guerra.federica@hsr.it
00390226438131

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion